IQVIA (IQV) Stock Forecast & Price Target

Q: What analysts cover IQVIA?

IQVIA has been rated by research analysts at Barclays , BMO Capital Markets , JPMorgan Chase & Co. , Mizuho , Morgan Stanley , Robert W. Baird , Royal Bank Of Canada , Stifel Nicolaus , TD Cowen , Truist Financial , UBS Group , Weiss Ratings , and William Blair in the past 90 days.

$260.26 +0.38 (+0.15%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$260.35 +0.08 (+0.03%)

As of 04:17 AM Eastern

Compare

IQVIA - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 17 Analyst Ratings

Sell
0

Hold
3

Buy
14

Based on 17 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 3 have given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for IQV.

Consensus Price Target

$274.31
5.40% Upside

According to the 17 analysts' twelve-month price targets for IQVIA, the average price target is $274.31. The highest price target for IQV is $345.00, while the lowest price target for IQV is $185.00. The average price target represents a forecasted upside of 5.40% from the current price of $260.26.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IQV Analyst Ratings Over Time

Type	Current Forecast 10/12/25 to 10/12/26	1 Month Ago 9/12/25 to 9/12/26	3 Months Ago 7/14/25 to 7/14/26	1 Year Ago 10/12/24 to 10/12/25
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	12 Buy rating(s)	13 Buy rating(s)	14 Buy rating(s)	17 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$274.31	$243.63	$225.71	$234.57
Forecasted Upside	5.40% Upside	-7.05% Downside	8.51% Upside	18.26% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Healthcare Companies	Broader Market
Consensus Rating Score	2.94	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	5.40% Upside	927.52% Upside	19.60% Upside
News Sentiment Rating	Neutral News See Recent IQV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/7/2026	Mizuho 3 of 5 stars	Ann Hynes 2 of 5 stars	Boost Target	Outperform	$275.00 ➝ $300.00	+16.55%
10/7/2026	Barclays 3 of 5 stars	Luke Sergott 5 of 5 stars	Boost Target	Overweight	$275.00 ➝ $300.00	+15.30%
9/30/2026	UBS Group 4 of 5 stars	Kevin Caliendo 3 of 5 stars	Initiated Coverage	Buy	$345.00	+28.31%
9/29/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Halsted Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$247.00 ➝ $319.00	+17.71%
9/28/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jailendra Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$300.00 ➝ $329.00	+22.28%
9/24/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C) ➝ Hold (C+)
9/17/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kallum Titchmarsh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$240.00 ➝ $270.00	-0.92%
7/29/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$233.00 ➝ $288.00	+16.49%
7/29/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sean Dodge Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$210.00 ➝ $270.00	+8.48%
7/29/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shlomo Rosenbaum Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$220.00 ➝ $276.00	+12.00%
Get the Latest News and Ratings for IQV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.
7/29/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$225.00 ➝ $285.00	+15.65%
7/29/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Coldwell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$252.00 ➝ $287.00	+16.98%
7/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/9/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$240.00	+14.43%
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$240.00	+16.25%
4/8/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Elizabeth Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$185.00	+10.93%
2/6/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Windley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$270.00 ➝ $255.00	+36.01%
2/6/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$230.00 ➝ $200.00	+6.68%
9/3/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jamie Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$214.00	+17.92%
2/3/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Larsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
12/20/2024	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeff Garro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$250.00	+30.53%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$255.00 ➝ $235.00	+17.54%
11/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$260.00 ➝ $248.00	+28.58%
11/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$280.00 ➝ $250.00	+20.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:34 AM ET.

Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 7, 2026. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

IQVIA Holdings Inc. recently launched IQVIA Life Science Models, a suite of purpose-built models designed to help life sciences companies predict clinical trial outcomes, leveraging the company's proprietary expert content and deep domain knowledge to enhance its competitive position in the healthcare analytics sector.
Analyst sentiment has shifted significantly in favor of the stock, with UBS Group upgrading IQVIA Holdings Inc. to a "strong-buy" rating and Royal Bank of Canada raising its price target from $247.00 to $319.00, indicating strong institutional confidence in the company's future performance and potential for upside.
The company demonstrated strong financial execution in its most recent quarterly report, posting earnings per share of $3.15, which exceeded the consensus estimate of $3.03, while revenue reached $4.37 billion, surpassing the expected $4.30 billion and reflecting an 8.7% year-over-year growth rate.
IQVIA Holdings Inc. has set its fiscal year 2026 guidance at $12.80 to $13.00 in earnings per share, which is above the consensus estimate of $12.57, suggesting that management expects continued strong profitability and operational efficiency throughout the year.
With the current stock price at $258.56, the valuation remains attractive relative to the company's growth trajectory, as the stock trades at a P/E ratio of 22.89, offering a reasonable entry point for investors seeking exposure to the growing life sciences tools and services industry.

IQVIA
Bear Case

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

IQVIA Holdings Inc. was recently fined $7.8 million for failing to properly anonymize health data, which poses a regulatory and reputational risk that could impact the company's ability to handle sensitive healthcare information and may lead to increased compliance costs.
The company carries a significant debt burden, with a debt-to-equity ratio of 2.18 and net debt of $14.1 billion, which could limit its financial flexibility and increase vulnerability to rising interest rates or economic downturns.
Insider selling has been notable, with several executives, including W. Richard Staub and Eric Sherbet, selling thousands of shares in recent months, which may signal a lack of confidence in the stock's near-term performance or a desire to diversify personal holdings.
Short interest in IQVIA Holdings Inc. has increased slightly, with 4,116,522 shares shorted as of the latest report, indicating that some investors are betting against the stock, which could create downward pressure on the share price if the short position is not covered.
The company's current ratio of 0.71 and quick ratio of 0.71 suggest potential liquidity challenges, as the company has less than one dollar in current assets for every dollar of current liabilities, which could affect its ability to meet short-term obligations.

IQV Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $274.31, with a high forecast of $345.00 and a low forecast of $185.00.

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 3 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IQV shares.

According to analysts, IQVIA's stock has a predicted upside of 5.40% based on their 12-month stock forecasts.

Over the previous 90 days, IQVIA's stock had 4 upgrades by analysts.

IQVIA has been rated by research analysts at Barclays, BMO Capital Markets, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and William Blair in the past 90 days.

Analysts like IQVIA more than other "healthcare" companies. The consensus rating for IQVIA is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how IQV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With IQVIA Recommendations

MarketBeat monitors more than a dozen sources for IQVIA analyst ratings, with the most recent rating issued on 10/7/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Stock Forecast & Price Target